Long Shortz with Rhythm: Non-invasive bowel cancer test delivers strong results

Tylah Tully chats with Dr Andy Feber, who works in Clinical R&D Translational Oncology and as an external advisor to Rhythm Biosciences (ASX:RHY).

Rhythm has just completed the final full system validation of its ColoSTAT, a diagnostic test for colorectal cancer.

Dr Feber explains how ColoSTAT could be used in clinics, explains the strong validation results showing over 90% sensitivity, and the tests potential to significantly reduce unnecessary colonoscopies – saving Australian paitents up to $500 million annually.

In the interview, Dr Feber outlines the next steps for Rhythm, including large-scale clinical trials to demonstrate ColoSTAT’s economic and clinical value.

This video was developed in collaboration with Rhythm Biosciences, a Stockhead client at the time of publishing.

The interviews and discussions in this video are opinions only and not financial or investment advice. Viewers should obtain independent advice based on their own circumstances before making any financial decisions